esuberaprost

esuberaprost

  • October 2018 •
  • 17 pages •
  • Report ID: 5780186 •
  • Format: PDF
Drug Overview
Esuberaprost (United Therapeutics) is an oral chemically stable prostacyclin analog targeting the prostaglandin I2 (PGI2) receptor. PGI2 agonists are potent vasodilators and platelet aggregation inhibitors, and also help relax smooth muscle cells by counteracting the effect of vasoconstrictive mediators.

Analyst Outlook
United Therapeutics has ceded a large advantage in the time required to develop and formulate esuberaprost as an oral prostacyclin. The pulmonary hypertension (PH) market now contains both Uptravi (selexipag; Johnson and Johnson/Nippon Shinyaku) and Orenitram (treprostinil; United Therapeutics) to occupy the oral prostacyclin niche, leaving esuberaprost a much narrower potential indication to be used as an adjunctive to inhaled Tyvaso (treprostinil; United Therapeutics/Mochida). This narrow therapeutic role, combined with questions surrounding esuberaprost’s efficacy, leaves the drug with restricted commercial potential